If you are running a clinical trial for Multiple Myeloma therapy, please consider including EasyM for better disease monitoring. It can provide:
- At least 10 months earlier detection of relapse
- An ideal complement to other MRD assays for a more accurate MRD status
- Ease of recruitment into the trial – since it does not require bone-marrow aspiration and is more accessible outside of major cities (only requires a blood draw)
- More frequent testing
Please contact us to discuss pricing and logistics for your clinical trial. Pricing is likely to be on the same order of magnitude as NGS-based tests but follows a different structure.